SR-142,948

SR-142,948

Systematic (IUPAC) name
2-([5-(2,6-dimethoxyphenyl)-1-[4-[3-(dimethylamino)propyl-methylcarbamoyl]-2-propan-2-ylphenyl]pyrazole-3-carbonyl]amino)adamantane-2-carboxylic acid
Identifiers
CAS Number	184162-64-9
PubChem	CID 5311451
IUPHAR/BPS	1580
ChemSpider	4470937
Chemical data
Formula	C39H51N5O6
Molar mass	685.850 g/mol
SMILES O=C(O)C6(NC(=O)c2nn(c1c(cc(C(=O)N(CCCN(C)C)C)cc1)C(C)C)c(c2)c3c(OC)cccc3OC)C4CC5CC6CC(C4)C5
InChI InChI=1S/C39H51N5O6/c1-23(2)29-21-26(37(46)43(5)15-9-14-42(3)4)12-13-31(29)44-32(35-33(49-6)10-8-11-34(35)50-7)22-30(41-44)36(45)40-39(38(47)48)27-17-24-16-25(19-27)20-28(39)18-24/h8,10-13,21-25,27-28H,9,14-20H2,1-7H3,(H,40,45)(H,47,48) Key:LWULHXVBLMWCHO-UHFFFAOYSA-N
(verify)

SR-142,948 is a drug used in scientific research which is a non-peptide antagonist selective for the neurotensin receptors, although not selective between subtypes.^[1] It has been used to study the role of neurotensin in the regulation of dopamine receptor activity^[2][3][4][5] and glutamate signalling in the brain,^[6][7] and in animal studies SR-142,948 blocked the effects of stimulant drugs,^[8] including MDMA.^[9]

References

1. Nalivaiko E, Michaud JC, Soubrié P, Le Fur G (October 1998). "Electrophysiological evidence for putative subtypes of neurotensin receptors in guinea-pig mesencephalic dopaminergic neurons". Neuroscience 86 (3): 799–811. doi:10.1016/S0306-4522(98)00084-0. PMID 9692718.
2. Alonso R, Gnanadicom H, Fréchin N, Fournier M, Le Fur G, Soubrié P (March 1999). "Blockade of neurotensin receptors suppresses the dopamine D1/D2 synergism on immediate early gene expression in the rat brain". The European Journal of Neuroscience 11 (3): 967–74. doi:10.1046/j.1460-9568.1999.00506.x. PMID 10103090.
3. Matsuyama S, Higashi H, Maeda H, Greengard P, Nishi A (April 2002). "Neurotensin regulates DARPP-32 thr34 phosphorylation in neostriatal neurons by activation of dopamine D1-type receptors". Journal of Neurochemistry 81 (2): 325–34. doi:10.1046/j.1471-4159.2002.00822.x. PMID 12064480.
4. Leonetti M, Brun P, Sotty F, Steinberg R, Soubrié P, Bert L, Renaud B, Suaud-Chagny MF (June 2002). "The neurotensin receptor antagonist SR 142948A blocks the efflux of dopamine evoked in nucleus accumbens by neurotensin ejection into the ventral tegmental area". Naunyn-Schmiedeberg's Archives of Pharmacology 365 (6): 427–33. doi:10.1007/s00210-002-0574-6. PMID 12070755.
5. Panayi F, Colussi-Mas J, Lambás-Señas L, Renaud B, Scarna H, Bérod A (May 2005). "Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization". Neuropsychopharmacology 30 (5): 871–9. doi:10.1038/sj.npp.1300638. PMID 15637639.
6. Matsuyama S, Fukui R, Higashi H, Nishi A (September 2003). "Regulation of DARPP-32 Thr75 phosphorylation by neurotensin in neostriatal neurons: involvement of glutamate signalling". The European Journal of Neuroscience 18 (5): 1247–53. doi:10.1046/j.1460-9568.2003.02859.x. PMID 12956723.
7. Yin HH, Adermark L, Lovinger DM (January 2008). "Neurotensin reduces glutamatergic transmission in the dorsolateral striatum via retrograde endocannabinoid signaling". Neuropharmacology 54 (1): 79–86. doi:10.1016/j.neuropharm.2007.06.004. PMC 2697967. PMID 17675102.
8. Reynolds SM, Geisler S, Bérod A, Zahm DS (July 2006). "Neurotensin antagonist acutely and robustly attenuates locomotion that accompanies stimulation of a neurotensin-containing pathway from rostrobasal forebrain to the ventral tegmental area". The European Journal of Neuroscience 24 (1): 188–96. doi:10.1111/j.1460-9568.2006.04791.x. PMID 16882016.
9. Marie-Claire C, Palminteri S, Romualdi P, Noble F (June 2008). "Effects of the selective neurotensin antagonist SR 142948A on 3,4-methylenedioxymethamphetamine-induced behaviours in mice". Neuropharmacology 54 (7): 1107–11. doi:10.1016/j.neuropharm.2008.03.001. PMID 18410947.